15.48
4.31%
0.64
アフターアワーズ:
15.48
前日終値:
$14.84
開ける:
$14.7
24時間の取引高:
798.18K
Relative Volume:
2.05
時価総額:
$419.31M
収益:
$157.75M
当期純損益:
$-29.73M
株価収益率:
5.1773
EPS:
2.99
ネットキャッシュフロー:
$-21.00M
1週間 パフォーマンス:
-10.05%
1か月 パフォーマンス:
-4.27%
6か月 パフォーマンス:
-41.78%
1年 パフォーマンス:
-49.69%
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
名前
Arcturus Therapeutics Holdings Inc
セクター
電話
(858) 900-2660
住所
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
ARCT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
15.48 | 419.31M | 157.75M | -29.73M | -21.00M | -1.16 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-08-12 | 開始されました | Leerink Partners | Outperform |
2023-12-13 | 開始されました | Canaccord Genuity | Buy |
2023-07-24 | 開始されました | William Blair | Outperform |
2023-05-11 | アップグレード | H.C. Wainwright | Neutral → Buy |
2022-11-14 | 再開されました | Wells Fargo | Overweight |
2022-11-10 | ダウングレード | Robert W. Baird | Neutral → Underperform |
2022-11-03 | アップグレード | Citigroup | Neutral → Buy |
2022-11-02 | アップグレード | Barclays | Underweight → Equal Weight |
2022-08-10 | ダウングレード | Raymond James | Mkt Perform → Underperform |
2022-07-19 | 再開されました | Cantor Fitzgerald | Overweight |
2022-05-11 | アップグレード | Robert W. Baird | Underperform → Neutral |
2022-04-21 | ダウングレード | Citigroup | Buy → Neutral |
2022-01-31 | アップグレード | Raymond James | Underperform → Mkt Perform |
2021-08-12 | ダウングレード | Raymond James | Mkt Perform → Underperform |
2021-08-11 | ダウングレード | Goldman | Neutral → Sell |
2021-08-10 | ダウングレード | Robert W. Baird | Neutral → Underperform |
2021-07-02 | 開始されました | Cantor Fitzgerald | Overweight |
2021-06-25 | 再開されました | Goldman | Neutral |
2021-06-21 | ダウングレード | Barclays | Equal Weight → Underweight |
2021-06-04 | 再開されました | Robert W. Baird | Neutral |
2021-02-17 | ダウングレード | B. Riley Securities | Neutral → Sell |
2021-01-19 | ダウングレード | B. Riley Securities | Buy → Neutral |
2021-01-15 | ダウングレード | B. Riley Securities | Buy → Neutral |
2021-01-07 | 開始されました | Wells Fargo | Overweight |
2020-12-29 | ダウングレード | Barclays | Overweight → Equal Weight |
2020-12-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2020-12-29 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2020-12-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2020-12-23 | ダウングレード | ROTH Capital | Buy → Sell |
2020-12-08 | 繰り返されました | B. Riley Securities | Buy |
2020-12-07 | 繰り返されました | B. Riley Securities | Buy |
2020-10-26 | 開始されました | Barclays | Overweight |
2020-10-06 | 開始されました | Citigroup | Buy |
2020-08-26 | 開始されました | Piper Sandler | Overweight |
2020-07-30 | 再開されました | ROTH Capital | Buy |
2020-07-16 | 開始されました | Raymond James | Outperform |
2020-07-13 | 開始されました | B. Riley FBR | Buy |
2020-06-09 | ダウングレード | WBB Securities | Buy → Hold |
2020-02-11 | 開始されました | Robert W. Baird | Outperform |
2020-02-07 | 開始されました | Guggenheim | Buy |
2020-02-06 | 開始されました | Guggenheim | Buy |
2019-04-05 | 開始されました | H.C. Wainwright | Buy |
2018-09-20 | アップグレード | WBB Securities | Buy → Strong Buy |
2018-01-22 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Arcturus Therapeutics Holdings Inc (ARCT) 最新ニュース
State Street Corp Sells 50,883 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate - Yahoo Finance
Arcturus Therapeutics stock hits 52-week low at $14.82 - Investing.com India
Wellington Management Group LLP Lowers Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics stock hits 52-week low at $14.82 By Investing.com - Investing.com Canada
Arcturus Therapeutics' (ARCT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StockTitan
Arcturus Therapeutics' SWOT analysis: mRNA vaccine stock faces pivotal year - Investing.com
Cantor Fitzgerald Reaffirms "Overweight" Rating for Arcturus Therapeutics (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings (NASDAQ:ARCT shareholders incur further losses as stock declines 9.8% this week, taking three-year losses to 63% - Simply Wall St
Fmr LLC Sells 112,516 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers - Yahoo Finance
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.
Arcturus Therapeutics (NASDAQ:ARCT) Shares Up 13.3%Here's Why - MarketBeat
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma - The Eastern Progress Online
Arcturus Therapeutics' SWOT analysis: vaccine maker's stock faces challenges, opportunities - Investing.com Nigeria
Portolan Capital Management LLC Sells 355,763 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
ARCT (Arcturus Therapeutics Holdings) Enterprise Value : $279.5 Mil (As of Dec. 04, 2024) - GuruFocus.com
Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
PDT Partners LLC Buys Shares of 75,144 Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conferences - BioSpace
Arcturus Therapeutics to Present at Major Healthcare Investor Conferences in December - StockTitan
GSA Capital Partners LLP Has $219,000 Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Buys 712,650 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Avian Flu: FDA Authorizes Self-Replicating Vaccine Trial to Bill Gates-Backed Company, "Study Can Proceed" - presskit.it
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data (NASDAQ:ARCT) - Seeking Alpha
Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan
Arcturus gains IND clearance for H5N1 influenza sa-RNA vaccine candidate - BioWorld Online
Possible Signal As Arcturus Therapeutics Holdings Insiders Sell US$1.6m In Stock - Simply Wall St
Another Avian Influenza mRNA Vaccine Candidate Advances - Precision Vaccinations
Arcturus Therapeutics Holdings Inc. Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - Marketscreener.com
What is HC Wainwright's Estimate for ARCT FY2028 Earnings? - MarketBeat
Arcturus Therapeutics’ (ARCT) Buy Rating Reiterated at HC Wainwright - Defense World
Arcturus Gets FDA Green Light for H5N1 Flu mRNA Vaccine Trial, Backed by BARDA - StockTitan
Earnings call: Arcturus Therapeutics reported a net loss of $6.9 million - Investing.com Australia
Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Arcturus Therapeutics Holdings Inc. - GuruFocus.com
Arcturus Therapeutics (NASDAQ:ARCT) Receives "Buy" Rating from HC Wainwright - MarketBeat
ARK Investment Management LLC Has $48.77 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Target Price from Brokerages - Defense World
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance
Arcturus Therapeutics Reports Q3 2024 Financial Results and Milestones - TipRanks
Arcturus Therapeutics Holdings Inc earnings beat by $0.31, revenue fell short of estimates - Investing.com
ARCTArcturus Therapeutics Holdings Inc. Latest Stock News & Market Updates - StockTitan
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arcturus Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Arcturus Therapeutics Holdings Inc (ARCT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):